Piper says Medicare final decision memo on LivaNova’s VNS ‘looks positive’

Piper Jaffray analyst Matt O’Brien said he has not had the opportunity to look through the entire Medicare final decision memorandum on LivaNova’s VNS therapy for treatment-resistant depression or speak with management yet, but his first impression is that the update “looks positive.” The agency moved from fixed primary or secondary endpoints to a number of research questions, which “seems like a softer approach,” O’Brien tells investors. He reiterated an Overweight rating on LivaNova shares.
https://thefly.com/landingPageNews.php?id=2865493